A Phase 1 interventional study of Islatravir in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-28.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The present study is designed to determine the effect of islatravir (ISL) [MK-8591] on methadone pharmacokinetics (PK). The primary objective is to assess whether ISL impacts the area under the plasma concentration time curve from dosing to 24 hours postdose (AUC0-24) of S-methadone and R-methadone in participants on oral methadone therapy. It is hypothesized that the plasma AUC0-24hr for S- and R-methadone will be similar after methadone alone compared to methadone and ISL 60 mg coadministration.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Methadone-maintained participants (20 to 200 mg \[locally-provided\] once daily \[QD\] from Day -14 to Day -1 and Day 10 to Day 15) receive methadone 20 to 200 mg QD on Day 1 to Day 9; ISL 60 mg is co-administered with methadone on Day 2.
Drug: Islatravir
ISL 30 mg x 2 (60 mg total) capsules taken by mouth.
Also known as: MK-8591
Dose-Normalized Area Under the Plasma Concentration Time Curve From 0-24 Hours Postdose (AUC0-24) of R-Methadone
The AUC0-24 of R-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
Time frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
Dose-Normalized AUC0-24 of S-Methadone
The AUC0-24hr of S-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
Time frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
Dose-Normalized Maximum Plasma Concentration (Cmax) of R-Methadone
The Cmax of R-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
Time frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
Dose-Normalized Plasma Concentration 24 Hours Postdose (C24) of R-Methadone
The C24 of R-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
Time frame: Days 1 and 2: 24 hours postdose
Time to Maximum Plasma Concentration (Tmax) of R-Methadone
The Tmax of R-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
Time frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
Dose-Normalized Cmax of S-Methadone
The Cmax of S-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
Time frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
Dose-Normalized C24 of S-Methadone
The C24 of S-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
Time frame: Days 1 and 2: 24 hours postdose
Tmax of S-Methadone
The Tmax of S-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
Time frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
Dose-Normalized AUC0-24 of Total Methadone
The AUC0-24hr of total methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
Time frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
Dose-Normalized Cmax of Total Methadone
The Cmax of total methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
Time frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
Dose-Normalized C24 of Total Methadone
The C24 of total methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
Time frame: Days 1 and 2: 24 hours postdose
Tmax of Total Methadone
The Tmax of total methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
Time frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
Number of Participants With Adverse Events (AEs) Following Methadone + ISL Coadministration
The number of participants with AEs will be determined for 14 days after coadministration of methadone and ISL on Day 2.
Time frame: Up to 16 days
Number of Participants Discontinuing Study Therapy Due to AEs Following Coadministration of Methadone and ISL
The number of participants discontinuing study therapy due to AEs after methadone + ISL on Day 2 will be determined.
Time frame: Up to 15 days
Methadone-maintained participants were recruited at 2 study sites in the United States.
| Milestone | Methadone + ISL |
|---|---|
| Started | 14 |
| Received isl on day 2 | 13 |
| Completed | 13 |
| Not completed | 1 |
| Withdrew: Physician decision | 1 |
The AUC0-24 of R-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
| ng*h/mL/mg | Methadone + ISL |
|---|---|
| Day 1: Methadone Alone | 61.9 (49.3 to 77.7) |
| Day 2: Methadone + ISL | 63.9 (52.2 to 78.1) |
The AUC0-24hr of S-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
| ng*h/mL/mg | Methadone + ISL |
|---|---|
| Day 1: Methadone Alone | 63.1 (48.9 to 81.5) |
| Day 2: Methadone + ISL | 65.1 (51.7 to 82.0) |
The Cmax of R-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
| ng/mL/mg | Methadone + ISL |
|---|---|
| Day 1: Methadone Alone | 3.64 (3.00 to 4.43) |
| Day 2: Methadone + ISL | 3.71 (3.14 to 4.40) |
The C24 of R-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
| ng/ml/mg | Methadone + ISL |
|---|---|
| Day 1: Methadone Alone | 2.09 (1.63 to 2.69) |
| Day 2: Methadone + ISL | 2.23 (1.78 to 2.78) |
The Tmax of R-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
| hours | Methadone + ISL |
|---|---|
| Day 1: Methadone Alone | 2.00 (1.47 to 3.00) |
| Day 2: Methadone + ISL | 2.00 (0.67 to 4.00) |
The Cmax of S-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
| ng/mL/mg | Methadone + ISL |
|---|---|
| Day 1: Methadone Alone | 4.25 (3.45 to 5.25) |
| Day 2: Methadone + ISL | 4.31 (3.49 to 5.32) |
The C24 of S-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
| ng/ml/mg | Methadone + ISL |
|---|---|
| Day 1: Methadone Alone | 1.91 (1.44 to 2.54) |
| Day 2: Methadone + ISL | 2.07 (1.60 to 2.68) |
The Tmax of S-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
| hours | Methadone + ISL |
|---|---|
| Day 1: Methadone Alone | 1.50 (1.02 to 3.00) |
| Day 2:Methadone + ISL | 2.00 (0.67 to 3.00) |
The AUC0-24hr of total methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
| ng*h/mL/mg | Methadone + ISL |
|---|---|
| Day 1: Methadone Alone | 126 (99.1 to 159) |
| Day 2: Methadone + ISL | 129 (105 to 160) |
The Cmax of total methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
| ng/mL/mg | Methadone + ISL |
|---|---|
| Day 1: Methadone Alone | 7.91 (6.48 to 9.66) |
| Day 2: Methadone + ISL | 8.02 (6.64 to 9.68) |
The C24 of total methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL). Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
| ng/ml/mg | Methadone + ISL |
|---|---|
| Day 1: Methadone Alone | 4.03 (3.10 to 5.23) |
| Day 2: Methadone + ISL | 4.32 (3.42 to 5.45) |
The Tmax of total methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
| hours | Methadone + ISL |
|---|---|
| Day 1: Methadone Alone | 2.00 (1.47 to 3.00) |
| Day 2: Methadone + ISL | 2.00 (0.67 to 3.00) |
The number of participants with AEs will be determined for 14 days after coadministration of methadone and ISL on Day 2.
| Participants | Methadone + ISL |
|---|---|
| Number of Participants With Adverse Events (AEs) Following Methadone + ISL Coadministration | 4 |
The number of participants discontinuing study therapy due to AEs after methadone + ISL on Day 2 will be determined.
| Participants | Methadone + ISL |
|---|---|
| Number of Participants Discontinuing Study Therapy Due to AEs Following Coadministration of Methadone and ISL | 0 |
Collected over Up to 16 days (up to 14 days after methadone + ISL coadministration on Day 2). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Methadone + ISL | 0/14 (0%) | 0/14 (0%) | 4/14 (28.6%) |
| Event | Methadone + ISL |
|---|---|
| Increased appetiteMetabolism and nutrition disorders | 2/14 |
| HeadacheNervous system disorders | 2/14 |
| VomitingGastrointestinal disorders | 1/14 |
| Infusion site extravasationGeneral disorders | 1/14 |
| AnxietyPsychiatric disorders | 1/14 |
| NightmarePsychiatric disorders | 1/14 |
| PapuleSkin and subcutaneous tissue disorders | 1/14 |
| PruritusSkin and subcutaneous tissue disorders | 1/14 |
| Age, Continuous(Years) | Methadone + ISL |
|---|---|
| Mean | 43.5 ± 12.0 |
| Sex: Female, Male(Participants) | Methadone + ISL |
|---|---|
| Female | 5 |
| Male | 9 |
| Ethnicity (NIH/OMB)(Participants) | Methadone + ISL |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 11 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Methadone + ISL |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 0 |
| White | 12 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Oct 2020 to primary completion in Jul 2021, 8 months.
Results were first posted in Dec 2023, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Islatravir